Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers

被引:3
|
作者
Quan, Baiyi [1 ]
Bailey, Morgan A. [1 ]
Mantyh, John [2 ]
Hsu, David S. [2 ]
Fitzgerald, Michael C. [1 ]
机构
[1] Duke Univ, Dept Chem, Durham, NC 27708 USA
[2] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
关键词
mass spectrometry; chemical denaturation; thermal denaturation; limited proteolysis; oxaliplatin; fatty acid synthase; elongation factor 2; RESISTANCE-RELATED PROTEIN; DRUG-RESISTANCE; GLOBAL ANALYSIS; CELL; OXALIPLATIN; TARGET; EXPRESSION; KINASE; LRP;
D O I
10.1021/acs.jproteome.3c00045
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Reported here is the application of three protein folding stability profiling techniques (including the stability of proteins from rates of oxidation, thermal protein profiling, and limited proteolysis approaches) to identify differentially stabilized proteins in six patient-derived colorectal cancer (CRC) cell lines with different oxaliplatin sensitivities and eight CRC patient-derived xenografts (PDXs) derived from two of the patient derived cell lines with different oxaliplatin sensitivities. Compared to conventional protein expression level analyses, which were also performed here, the stability profiling techniques identified both unique and novel proteins and cellular components that differentiated the sensitive and resistant samples including 36 proteins that were differentially stabilized in at least two techniques in both the cell line and PDX studies of oxaliplatin resistance. These 36 differentially stabilized proteins included 10 proteins previously connected to cancer chemoresistance. Two differentially stabilized proteins, fatty acid synthase and elongation factor 2, were functionally validated in vitro and found to be druggable protein targets with biological functions that can be modulated to improve the efficacy of CRC chemotherapy. These results add to our understanding of CRC oxaliplatin resistance, suggest biomarker candidates for predicting oxaliplatin sensitivity in CRC, and inform new strategies for overcoming chemoresistance in CRC.
引用
收藏
页码:1923 / 1935
页数:13
相关论文
共 50 条
  • [31] Protein profiling in human sera for identification of potential lung cancer biomarkers using antibody microarray
    Han, Min-Kyu
    Oh, Young-Hee
    Kang, Jimin
    Kim, Young-Pil
    Seo, Soowon
    Kim, Jhingook
    Park, KeunChil
    Kim, Hak-Sung
    PROTEOMICS, 2009, 9 (24) : 5544 - 5552
  • [32] Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer
    Fijneman, Remond J. A.
    de Wit, Meike
    Pourghiasian, Maral
    Piersma, Sander R.
    Pham, Thang V.
    Warmoes, Marc O.
    Lavaei, Mehrdad
    Piso, Chloe
    Smit, Fiona
    Delis-van Diemen, Pien M.
    van Turenhout, Sietze T.
    Droste, Jochim S. Terhaar Sive
    Mulder, Chris J. J.
    Blankenstein, Marinus A.
    Robanus-Maandag, Els C.
    Smits, Ron
    Fodde, Riccardo
    van Hinsbergh, Victor W. M.
    Meijer, Gerrit A.
    Jimenez, Connie R.
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2613 - 2624
  • [33] Increased chemoresistance via snail-raf kinase inhibitor protein signaling in colorectal cancer in response to a nicotine derivative
    Lee, Tsai-Yu
    Liu, Chia-Lin
    Chang, Yun-Ching
    Nieh, Shin
    Lin, Yaoh-Shiang
    Jao, Shu-Wen
    Chen, Su-Feng
    Liu, Tsung-Yun
    ONCOTARGET, 2016, 7 (17) : 23512 - 23520
  • [34] Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection
    Rodia, Maria Teresa
    Ugolini, Giampaolo
    Mattei, Gabriella
    Montroni, Isacco
    Zattoni, Davide
    Ghignone, Federico
    Veronese, Giacomo
    Marisi, Giorgia
    Lauriola, Mattia
    Strippoli, Pierluigi
    Solmi, Rossella
    ONCOTARGET, 2016, 7 (21) : 30295 - 30306
  • [35] Exploratory Study Identifies Matrix Metalloproteinase-14 and-9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer
    Suenaga, Mitsukuni
    Mashima, Tetsuo
    Kawata, Naomi
    Dan, Shingo
    Seimiya, Hiroyuki
    Yamaguchi, Kensei
    CANCERS, 2024, 16 (16)
  • [36] Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B
    Daemen, Anneleen
    Udyavar, Akshata R.
    Sandmann, Thomas
    Li, Congfen
    Bosch, Linda J. W.
    O'Gorman, William
    Li, Yijin
    Au-Yeung, Amelia
    Takahashi, Chikara
    Kabbarah, Omar
    Bourgon, Richard
    Hegde, Priti
    Bais, Carlos
    Das Thakur, Meghna
    PLOS ONE, 2021, 16 (12):
  • [37] Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression
    de Wit, Meike
    Jimenez, Connie R.
    Carvalho, Beatriz
    Belien, Jeroen A. M.
    Delis-van Diemen, Pien M.
    Mongera, Sandra
    Piersma, Sander R.
    Vikas, Maindad
    Navani, Sanjay
    Ponten, Fredrik
    Meijer, Gerrit A.
    Fijneman, Remond J. A.
    GUT, 2012, 61 (06) : 855 - 864
  • [38] Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
    Nixon, Andrew B.
    Sibley, Alexander B.
    Liu, Yingmiao
    Hatch, Ace J.
    Jiang, Chen
    Mulkey, Flora
    Starr, Mark D.
    Brady, John C.
    Niedzwiecki, Donna
    Venook, Alan P.
    Baez-Diaz, Luis
    Lenz, Heinz-Josef
    O'Neil, Bert H.
    Innocenti, Federico
    Meyerhardt, Jeffrey A.
    O'Reilly, Eileen M.
    Owzar, Kouros
    Hurwitz, Herbert, I
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2779 - 2788
  • [39] Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer
    Topno, Rachel
    Nazam, Nazia
    Kumari, Pallawi
    Kumar, Manoj
    Agarwal, Pallavi
    CANCER BIOMARKERS, 2021, 32 (04) : 491 - 504
  • [40] A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer
    Sandra Kendzia
    Susanne Franke
    Tarek Kröhler
    Nicole Golob-Schwarzl
    Caroline Schweiger
    Anna M. Toeglhofer
    Christina Skofler
    Stefan Uranitsch
    Amin El-Heliebi
    Julia Fuchs
    Andreas Punschart
    Philipp Stiegler
    Marlen Keil
    Jens Hoffmann
    David Henderson
    Hans Lehrach
    Marie-Laure Yaspo
    Christoph Reinhard
    Reinhold Schäfer
    Ulrich Keilholz
    Christian Regenbrecht
    Rudolf Schicho
    Peter Fickert
    Sigurd F. Lax
    Frank Erdmann
    Marcel H. Schulz
    Alexandra K. Kiemer
    Johannes Haybaeck
    Sonja M. Kessler
    Molecular Cancer, 22